跳至主要内容
临床试验/NCT06126991
NCT06126991招募中1 期

Organ Protective Effect of Histamine H1 Receptor Antagonist In Patients With Severe Burns: A Clinical Study

Ruijin Hospital1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2024年1月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
32
试验地点
1
主要终点
APACHE II on Day 7

研究概览

简要总结

This prospective clinical trial aims to investigate the organ protective effects of cetirizine in patients with severe burns.

详细描述

This is a prospective, randomized, single-blind, parallel-controlled clinical trial. The global objective is to compare the organ protective effects of the sedation and analgesia regimen (midazolam, fentanyl) with the modified sedation and analgesia regimen (midazolam, fentanyl, cetirizine) in patients with severe burns (≥30% TBSA). Participants will receive the intervention from admission to 72 hours post-burn. Researchers will take the APACHE II scores on days 7 after admission as the main outcomes. Researchers will also take other supplementary examination results into account, including liver enzyme, myocardial enzyme, renal function, haemodynamic index, coagulation function, and pulmonary interstitial edema.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
12 Years 至 90 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed and dated informed consent form
  • Commitment to comply with the procedures and cooperation during the course
  • TBSA >30% and admitted within the first day after burns
  • No severe compound injuries

排除标准

  • History of allergy to drugs in the trial
  • Postoperative complications that would interfere with the observation
  • Mental illness and severe heart disease, hypertension
  • Serious genetic diseases
  • Incomplete clinical information (unclear diagnosis, incomplete medical history, incomplete medication records, etc.)
  • Pregnancy/lactation
  • Malignant tumors
  • Organ insufficiency due to previous chronic diseases such as hypertension, diabetes mellitus or non-burning factors
  • Serious adverse reactions
  • Self-requested withdrawal

研究组 & 干预措施

The Modified Sedation and Analgesia Regimen Group

Experimental

midazolam, fentanyl, cetirizine

干预措施: Cetirizine (Drug)

The Modified Sedation and Analgesia Regimen Group

Experimental

midazolam, fentanyl, cetirizine

干预措施: Midazolam and Fentanyl (Drug)

The Sedation and Analgesia Regimen Group

Active Comparator

midazolam, fentanyl

干预措施: Midazolam and Fentanyl (Drug)

结局指标

主要结局

APACHE II on Day 7

时间窗: Day 7

Observation of APACHE II scores of patients in each group 7 days after admission. The APACHE II (Acute Physiology And Chronic Health Evaluation II) is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements. Higher scores correspond to more severe disease and a higher risk of death.

次要结局

  • Stroke Volume(Day 7)
  • Urinary Output(Day 7)
  • Blood L-lactate(Day 7)
  • Base Excess (BE)(Day 7)
  • Stroke Volume Variation(Day 7)
  • Global End-Diastolic Volume(Day 7)
  • Central Venous Pressure(Day 7)
  • Cardiac Function Index(Day 7)
  • Pulmonary interstitial edema(Day 7)
  • SOFA Score(Day 7)
  • Body Temperature(Day 7)
  • Heart Rate(Day 7)
  • Respiratory Rate(Day 7)
  • Leukocyte Count(Day 7)
  • Blood CRP(Day 7)
  • Blood Calcitoninogen(Day 7)
  • Mechanical Ventilation Duration(Day 28)
  • Mortality(Day 28)
  • Sepsis Rate(Day 28)
  • Oxygen Saturation(Day 7)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验